- Home
- RCKT vs PROK Comparison
RCKT vs PROK Comparison
Compare RCKT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | PROK |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.2M | 316.0M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RCKT | PROK |
|---|---|---|
| Price | $2.62 | $1.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $29.73 | $7.40 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.37 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $64.28 | N/A |
| P/E Ratio | $4.08 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.53 | $1.30 |
| 52 Week High | $5.45 | $3.48 |
Technical Indicators
Market Signals| Indicator | RCKT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 27.44 | 41.05 |
| Support Level | N/A | $1.56 |
| Resistance Level | $3.67 | $2.01 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 2.89 | 0.00 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.